Nina Devlin News
-
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.
-
Actavis Inc., the generic drugmaker whose merger negotiations with Valeant Pharmaceuticals International Inc. stalled over price, may deserve the industry’s second-best valuation ever in a deal.
-
Christie Hefner, former chief executive officer of Playboy Enterprises Inc., said she was shocked as her husband of 15 years, William Marovitz, confessed to her that he was being investigated for suspicious trading in Playboy shares. They were in their apartment atop a 42-story Lincoln Park tower overlooking the glittering Chicago skyline and Lake Michigan on a March evening in 2010.
-
Former day trader Jamil Bouchareb was sentenced to 30 months in prison for trading on stock tips gleaned from the wife of a former Lehman Brothers Holdings Inc. salesman.
-
Samsung Electronics Co.’s bid to block sales of Apple Inc. iPads and iPhones in Japan was rejected by a Tokyo judge in the continuing global patent fight between the two biggest smartphone makers.
-
Lupin Ltd. lost its appeals court bid to prevent Mylan Inc. from selling a generic version of the drug Antara, used to treat high cholesterol levels.
-
Ex-Lehman Brothers Holdings Inc. broker Matthew Devlin, who cooperated with a U.S. probe of insider trading, was sentenced to three years of probation after prosecutors cited his “noteworthy” assistance.
-
Par Pharmaceutical Cos., a maker of generic drugs, agreed to be acquired for $1.9 billion by TPG Capital as the private-equity firm looks to gain from efforts to curtail health-care costs.
-
AT&T Inc.’s plan to buy T-Mobile USA Inc. was placed in further jeopardy after a federal judge agreed to consider a request by the U.S. to postpone or dismiss its lawsuit seeking to block the deal.
-
AstraZeneca Plc won a U.S. court ruling that will help ward off some generic competition to the extended-release version of its Seroquel antipsychotic drug until a patent expires in 2017.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page